Related Content
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightOctober 13, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA’s Proposed Phaseout Policy – Key Considerations & Open Questions
- InsightOctober 6, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule
- AlertSeptember 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
- InsightJune 29, 2023
A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond
- InsightMay 24, 2023
Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions
- AlertApril 5, 2023
CMS Issues Guidance and Solicits Comment on the 2026 Inflation Reduction Act Part D Negotiation Process
- AlertMarch 15, 2023
The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies
- Press ReleaseMay 2, 2024
Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Awards and RankingsMarch 20, 2024
The American Lawyer Names Rachael Bushey and Jennifer Porter 2024 Dealmakers of the Year
- In the PressMarch 6, 2024
Eidos Therapeutics Signs Exclusive License Agreement with Bayer
- Press ReleaseFebruary 9, 2024
BridgeBio Pharma and QED Therapeutics License Skeletal Dysplasias Treatments to Kyowa Kirin for an Upfront Payment of $100 Million Plus Milestones
- Press ReleaseFebruary 1, 2024
AVROBIO To Combine With Tectonic Therapeutic In All-Stock Transaction
- Press ReleaseJanuary 16, 2024
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential